Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 9/20 | 0.57 |
| ▸ | BCHE | P06276 | 9/20 | 0.52 |
| ▸ | BACE1 | P56817 | 8/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | SCN4A | P35499 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | CCR3 | P51677 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1993388 | 1.00 | ACHE (0.57) | ACHEBCHEBACE1ALDH1A1SCN4A | |
| SCHEMBL20019719 | 1.00 | ACHE (0.57) | ACHEBCHEBACE1ALDH1A1SCN4A | |
| SCHEMBL14018259 | 1.00 | ACHE (0.57) | ACHEBCHEBACE1ALDH1A1SCN4A | |
| SCHEMBL20019720 | 1.00 | ACHE (0.57) | ACHEBCHEBACE1ALDH1A1SCN4A | |
| SCHEMBL12395260 | 1.00 | ACHE (0.57) | ACHEBCHEBACE1ALDH1A1SCN4A | |
| SCHEMBL690845 | 1.00 | ACHE (0.57) | ACHEBCHEBACE1ALDH1A1SCN4A | |
| Hydrochloric Acid SCHEMBL20597421 | 0.98 | ACHE (0.55) | ACHEBCHEBACE1ALDH1A1SCN4A | |
| Hydrochloric Acid SCHEMBL22500017 | 0.98 | ACHE (0.55) | ACHEBCHEBACE1ALDH1A1SCN4A | |
| Hydrochloric Acid SCHEMBL2148084 | 0.98 | ACHE (0.55) | ACHEBCHEBACE1ALDH1A1SCN4A | |
| Hydrochloric Acid SCHEMBL1373413 | 0.98 | ACHE (0.55) | ACHEBCHEBACE1ALDH1A1SCN4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 194 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12227478-B2 | Processes for preparing (3R,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine or a salt thereof and processes for preparing tofacitinib using the same | YUHAN CORPORATION (KR) | 2025-02-18 | — | — | US | claimed |
| CN-113614069-B | Process for preparing (3R, 4R) -1-benzyl-N, 4-dimethylpiperidin-3-amine or a salt thereof and process for preparing tofacitinib using the same | 柳韩洋行 | 2024-05-28 | — | — | CN | claimed |
| EP-3927689-B1 | PROCESSES FOR PREPARING (3R,4R)-1-BENZYL-N,4-DIMETHYLPIPERIDIN-3-AMINE OR A SALT THEREOF AND PROCESSES FOR PREPARING TOFACITINIB USING THE SAME | YUHAN CORP (KR) | 2024-01-24 | — | — | EP | claimed |
| CN-114807071-B | Enzymatic preparation method of tofacitinib key intermediate | 中国科学院天津工业生物技术研究所 | 2023-10-20 | — | — | CN | claimed |
| CN-113930404-B | Method for synthesizing chiral tofacitinib citrate intermediate by enzymatic method | 浙江乐普药业股份有限公司 | 2023-10-13 | — | — | CN | claimed |
| CN-115808472-A | Method for analyzing and detecting impurity BMPA-3 in R-BMPA | 江苏万邦生化医药集团有限责任公司 | 2023-03-17 | — | — | CN | claimed |
| CN-114807071-A | Enzymatic preparation method of tofacitinib key intermediate | 中国科学院天津工业生物技术研究所 | 2022-07-29 | — | — | CN | claimed |
| CN-114685515-A | Preparation method of tofacitinib | 上海蓝乐鸟实业有限公司 | 2022-07-01 | — | — | CN | claimed |
| CN-113125587-B | Tofacitinib intermediate and detection method of enantiomer thereof | 成都百裕制药股份有限公司 | 2022-05-24 | — | — | CN | claimed |
| US-20220144774-A1 | PROCESSES FOR PREPARING (3R,4R)-1-BENZYL-N,4-DIMETHYLPIPERIDIN-3-AMINE OR A SALT THEREOF AND PROCESSES FOR PREPARING TOFACITINIB USING THE SAME | YUHAN CORPORATION (KR) | 2022-05-12 | — | — | US | claimed |
| EP-3927689-A1 | PROCESSES FOR PREPARING (3R,4R)-1-BENZYL-N,4-DIMETHYLPIPERIDIN-3-AMINE OR A SALT THEREOF AND PROCESSES FOR PREPARING TOFACITINIB USING THE SAME | Yuhan Corporation (KR) | 2021-12-29 | — | — | EP | claimed |
| WO-2020204647-A1 | PROCESSES FOR PREPARING (3R,4R)-1-BENZYL-N,4-DIMETHYLPIPERIDIN-3-AMINE OR A SALT THEREOF AND PROCESSES FOR PREPARING TOFACITINIB USING THE SAME | YUHAN CORPORATION (KR) | 2020-10-08 | — | — | WO | claimed |
| EP-3421455-B1 | IMPROVED PROCESS FOR THE PREPARATION OF CHIRAL 3-AMINO-PIPERIDINS, USEFUL INTERMEDIATES FOR THE PREPARATION OF TOFACITINIB | FIS FABBRICA ITALIANA SINTETICI SPA (IT) | 2019-03-27 | — | — | EP | claimed |
| US-20190002407-A1 | PROCESS FOR THE PREPARATION OF CHIRAL 3-AMINO-PIPERIDINS, USEFUL INTERMEDIATES FOR THE PREPARATION OF TOFACITINIB | F.I.S. - FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2019-01-03 | — | — | US | claimed |
| EP-3421455-A1 | IMPROVED PROCESS FOR THE PREPARATION OF CHIRAL 3-AMINO-PIPERIDINS, USEFUL INTERMEDIATES FOR THE PREPARATION OF TOFACITINIB | F.I.S.- Fabbrica Italiana Sintetici S.p.A. (IT) | 2019-01-02 | — | — | EP | claimed |
| US-20160122354-A1 | PROCESS FOR THE PREPARATION OF (3R,4R)-4-METHYL-3-(METHYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL-AMINO)-ß-OXO-1-PIPERIDINEPROPANENITRILE AND ITS SALTS | THIRUMALAI RAJAN SRINIVASAN (IN) | 2016-05-05 | — | — | US | claimed |
| US-20160102057-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF (3R,4R)-(1-BENZYL-4-METHYLPIPERIDIN-3-YL)-METHYLAMINE | UNICHEM LABORATORIES LIMITED (IN) | 2016-04-14 | — | — | US | claimed |
| EP-2994454-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF (3R,4R)-(1-BENZYL-4-METHYLPIPERIDIN-3-YL)-METHYLAMINE | UNICHEM LABORATORIES LIMITED (IN) | 2016-03-16 | — | — | EP | claimed |
| WO-2015087201-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF (3R,4R)-(1-BENZYL-4-METHYLPIPERIDIN-3-YL)-METHYLAMINE | UNICHEM LABORATORIES LIMITED (IN) | 2015-06-18 | — | — | WO | claimed |
| US-20260062410-A1 | SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME | ACLARIS THERAPEUTICS INC (US) | 2026-03-05 | — | — | US | disclosed |
| EP-4656249-A2 | PYRAZOLOPYRIMIDINE DERIVATIVES AS KINASE INHIBITOR | Daewoong Pharmaceutical Co., Ltd. (KR) | 2025-12-03 | — | — | EP | disclosed |
| CN-113939295-B | Pyridazinones and methods of use thereof | 金翅雀生物公司 | 2025-05-16 | — | — | CN | disclosed |
| US-12281111-B2 | Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same | ACLARIS THERAPEUTICS, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| US-12227478-B2 | Processes for preparing (3R,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine or a salt thereof and processes for preparing tofacitinib using the same | YUHAN CORPORATION (KR) | 2025-02-18 | — | — | US | disclosed |
| US-12227478-B2 | Processes for preparing (3R,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine or a salt thereof and processes for preparing tofacitinib using the same | YUHAN CORPORATION (KR) | 2025-02-18 | — | — | US | disclosed |
| US-12227478-B2 | Processes for preparing (3R,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine or a salt thereof and processes for preparing tofacitinib using the same | YUHAN CORPORATION (KR) | 2025-02-18 | — | — | US | disclosed |
| CN-119119039-A | Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same | 阿克拉瑞斯治疗股份有限公司 | 2024-12-13 | — | — | CN | disclosed |
| CN-111566095-B | Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same | 阿克拉瑞斯治疗股份有限公司 | 2024-09-27 | — | — | CN | disclosed |
| US-20240279179-A1 | SYNTHESIS AND USE OF 1-BENZYL-4-METHYL-5-ALKOXY-1,2,3,6-TETRAHYDROPYRIDINE DERIVATIVE | ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) | 2024-08-22 | — | — | US | disclosed |
| EP-4414365-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | Goldfinch Bio, Inc. (US) | 2024-08-14 | — | — | EP | disclosed |
| CN-115038703-B | Preparation method of tofacitinib and intermediate product thereof | 阿尔第实业有限公司 | 2024-08-06 | — | — | CN | disclosed |
| CN-115124455-B | Preparation method of tofacitinib intermediate | 南通常佑药业科技有限公司 | 2024-07-26 | — | — | CN | disclosed |
| CN-113614069-B | Process for preparing (3R, 4R) -1-benzyl-N, 4-dimethylpiperidin-3-amine or a salt thereof and process for preparing tofacitinib using the same | 柳韩洋行 | 2024-05-28 | — | — | CN | disclosed |
| CN-113614069-B | Process for preparing (3R, 4R) -1-benzyl-N, 4-dimethylpiperidin-3-amine or a salt thereof and process for preparing tofacitinib using the same | 柳韩洋行 | 2024-05-28 | — | — | CN | disclosed |
| CN-113614069-B | Process for preparing (3R, 4R) -1-benzyl-N, 4-dimethylpiperidin-3-amine or a salt thereof and process for preparing tofacitinib using the same | 柳韩洋行 | 2024-05-28 | — | — | CN | disclosed |
| CN-117756806-A | Preparation method of tofacitinib intermediate | 山东新时代药业有限公司 | 2024-03-26 | — | — | CN | disclosed |
| CN-117756806-A | Preparation method of tofacitinib intermediate | 山东新时代药业有限公司 | 2024-03-26 | — | — | CN | disclosed |
| EP-3478687-B1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS KINASE INHIBITOR | DAEWOONG PHARMACEUTICAL CO LTD (KR) | 2024-03-20 | — | — | EP | disclosed |
| US-20240067643-A1 | SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME | ACLARIS THERAPEUTICS, INC. | 2024-02-29 | — | — | US | disclosed |
| US-20240067643-A1 | SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME | ACLARIS THERAPEUTICS, INC. | 2024-02-29 | — | — | US | disclosed |
| US-20240067643-A1 | SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME | ACLARIS THERAPEUTICS, INC. | 2024-02-29 | — | — | US | disclosed |
| EP-3852533-B1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO INC (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-3927689-B1 | PROCESSES FOR PREPARING (3R,4R)-1-BENZYL-N,4-DIMETHYLPIPERIDIN-3-AMINE OR A SALT THEREOF AND PROCESSES FOR PREPARING TOFACITINIB USING THE SAME | YUHAN CORP (KR) | 2024-01-24 | — | — | EP | disclosed |
| EP-3927689-B1 | PROCESSES FOR PREPARING (3R,4R)-1-BENZYL-N,4-DIMETHYLPIPERIDIN-3-AMINE OR A SALT THEREOF AND PROCESSES FOR PREPARING TOFACITINIB USING THE SAME | YUHAN CORP (KR) | 2024-01-24 | — | — | EP | disclosed |
| EP-3927689-B1 | PROCESSES FOR PREPARING (3R,4R)-1-BENZYL-N,4-DIMETHYLPIPERIDIN-3-AMINE OR A SALT THEREOF AND PROCESSES FOR PREPARING TOFACITINIB USING THE SAME | YUHAN CORP (KR) | 2024-01-24 | — | — | EP | disclosed |
| EP-3927689-C0 | PROCESSES FOR PREPARING (3R,4R)-1-BENZYL-N,4-DIMETHYLPIPERIDIN-3-AMINE OR A SALT THEREOF AND PROCESSES FOR PREPARING TOFACITINIB USING THE SAME | YUHAN CORP (KR) | 2024-01-24 | — | — | EP | disclosed |
| US-11827598-B1 | Preparation method of tofacitinib citrate | CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO. LTD. (TW) | 2023-11-28 | — | — | US | disclosed |
| EP-4269391-A1 | SYNTHESIS AND USE OF 1-BENZYL-4-METHYL-5-ALKOXY-1,2,3,6-TETRAHYDROPYRIDINE DERIVATIVE | Zhejiang Ausun Pharmaceutical Co., Ltd. (CN) | 2023-11-01 | — | — | EP | disclosed |
| EP-4269391-A1 | SYNTHESIS AND USE OF 1-BENZYL-4-METHYL-5-ALKOXY-1,2,3,6-TETRAHYDROPYRIDINE DERIVATIVE | Zhejiang Ausun Pharmaceutical Co., Ltd. (CN) | 2023-11-01 | — | — | EP | disclosed |
| CN-114807071-B | Enzymatic preparation method of tofacitinib key intermediate | 中国科学院天津工业生物技术研究所 | 2023-10-20 | — | — | CN | disclosed |
| CN-113930404-B | Method for synthesizing chiral tofacitinib citrate intermediate by enzymatic method | 浙江乐普药业股份有限公司 | 2023-10-13 | — | — | CN | disclosed |
| CN-113930404-B | Method for synthesizing chiral tofacitinib citrate intermediate by enzymatic method | 浙江乐普药业股份有限公司 | 2023-10-13 | — | — | CN | disclosed |
| US-11739086-B2 | Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same | ACLARIS THERAPEUTICS, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11739086-B2 | Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same | ACLARIS THERAPEUTICS, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11739086-B2 | Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same | ACLARIS THERAPEUTICS, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| CN-115808472-A | Method for analyzing and detecting impurity BMPA-3 in R-BMPA | 江苏万邦生化医药集团有限责任公司 | 2023-03-17 | — | — | CN | disclosed |
| US-20220402924-A1 | PROCESS FOR THE PREPARATION OF TOFACITINIB AND INTERMEDIATES THEREOF | AARTI PHARMALABS LIMITED (IN) | 2022-12-22 | — | — | US | disclosed |
| US-20220402924-A1 | PROCESS FOR THE PREPARATION OF TOFACITINIB AND INTERMEDIATES THEREOF | AARTI PHARMALABS LIMITED (IN) | 2022-12-22 | — | — | US | disclosed |
| EP-3927689-A4 | PROCESSES FOR PREPARING (3R,4R)-1-BENZYL-N,4-DIMETHYLPIPERIDIN-3-AMINE OR A SALT THEREOF AND PROCESSES FOR PREPARING TOFACITINIB USING THE SAME | Yuhan Corporation (KR) | 2022-11-30 | — | — | EP | disclosed |
| CN-115124455-A | Preparation method of tofacitinib intermediate | 南通常佑药业科技有限公司 | 2022-09-30 | — | — | CN | disclosed |
| CN-115038703-A | Preparation method of tofacitinib and intermediate product thereof | 阿尔第实业有限公司 | 2022-09-09 | — | — | CN | disclosed |
| EP-4051681-A1 | PROCESS FOR THE PREPARATION OF TOFACITINIB AND INTERMEDIATES THEREOF | Aarti Industries Limited (IN) | 2022-09-07 | — | — | EP | disclosed |
| CN-114807071-A | Enzymatic preparation method of tofacitinib key intermediate | 中国科学院天津工业生物技术研究所 | 2022-07-29 | — | — | CN | disclosed |
| CN-114685510-A | Tofacitinib intermediate and preparation method thereof | 上海科胜药物研发有限公司 | 2022-07-01 | — | — | CN | disclosed |
| CN-114685515-A | Preparation method of tofacitinib | 上海蓝乐鸟实业有限公司 | 2022-07-01 | — | — | CN | disclosed |
| CN-114685515-A | Preparation method of tofacitinib | 上海蓝乐鸟实业有限公司 | 2022-07-01 | — | — | CN | disclosed |
| CN-113125587-B | Tofacitinib intermediate and detection method of enantiomer thereof | 成都百裕制药股份有限公司 | 2022-05-24 | — | — | CN | disclosed |
| US-20220153743-A1 | PROCESS FOR PREPARATION OF TOFACITINIB AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | INTAS PHARMACEUTICALS LTD. (IN) | 2022-05-19 | — | — | US | disclosed |
| US-20220152031-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. | 2022-05-19 | — | — | US | disclosed |
| US-20220144774-A1 | PROCESSES FOR PREPARING (3R,4R)-1-BENZYL-N,4-DIMETHYLPIPERIDIN-3-AMINE OR A SALT THEREOF AND PROCESSES FOR PREPARING TOFACITINIB USING THE SAME | YUHAN CORPORATION (KR) | 2022-05-12 | — | — | US | disclosed |
| US-20220144774-A1 | PROCESSES FOR PREPARING (3R,4R)-1-BENZYL-N,4-DIMETHYLPIPERIDIN-3-AMINE OR A SALT THEREOF AND PROCESSES FOR PREPARING TOFACITINIB USING THE SAME | YUHAN CORPORATION (KR) | 2022-05-12 | — | — | US | disclosed |
| US-20220144774-A1 | PROCESSES FOR PREPARING (3R,4R)-1-BENZYL-N,4-DIMETHYLPIPERIDIN-3-AMINE OR A SALT THEREOF AND PROCESSES FOR PREPARING TOFACITINIB USING THE SAME | YUHAN CORPORATION (KR) | 2022-05-12 | — | — | US | disclosed |
| CN-109503462-B | Synthesis method of tofacitinib intermediate (3R, 4R) -N, 4-dimethyl-1-benzyl-3-piperidylamine | 内蒙古京东药业有限公司 | 2022-03-25 | — | — | CN | disclosed |
| CN-109503462-B | Synthesis method of tofacitinib intermediate (3R, 4R) -N, 4-dimethyl-1-benzyl-3-piperidylamine | 内蒙古京东药业有限公司 | 2022-03-25 | — | — | CN | disclosed |
| CN-109503462-B | Synthesis method of tofacitinib intermediate (3R, 4R) -N, 4-dimethyl-1-benzyl-3-piperidylamine | 内蒙古京东药业有限公司 | 2022-03-25 | — | — | CN | disclosed |
| EP-3950691-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS KINASE INHIBITOR | Daewoong Pharmaceutical Co., Ltd. (KR) | 2022-02-09 | — | — | EP | disclosed |
| US-20220024917-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. | 2022-01-27 | — | — | US | disclosed |
| EP-3927689-A1 | PROCESSES FOR PREPARING (3R,4R)-1-BENZYL-N,4-DIMETHYLPIPERIDIN-3-AMINE OR A SALT THEREOF AND PROCESSES FOR PREPARING TOFACITINIB USING THE SAME | Yuhan Corporation (KR) | 2021-12-29 | — | — | EP | disclosed |
| EP-3927689-A1 | PROCESSES FOR PREPARING (3R,4R)-1-BENZYL-N,4-DIMETHYLPIPERIDIN-3-AMINE OR A SALT THEREOF AND PROCESSES FOR PREPARING TOFACITINIB USING THE SAME | Yuhan Corporation (KR) | 2021-12-29 | — | — | EP | disclosed |
| US-20210284637-A1 | SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME | ACLARIS THERAPEUTICS, INC. | 2021-09-16 | — | — | US | disclosed |
| US-20210284637-A1 | SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME | ACLARIS THERAPEUTICS, INC. | 2021-09-16 | — | — | US | disclosed |
| US-11046690-B2 | Pyridazinones and methods of use thereof | GOLDFINCH BIO, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| WO-2021084556-A1 | Process for the preparation of tofacitinib and intermediates thereof | AARTI INDUSTRIES LIMITED (IN) | 2021-05-06 | — | — | WO | disclosed |
| US-10981906-B2 | Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same | ACLARIS THERAPEUTICS, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-10981906-B2 | Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same | ACLARIS THERAPEUTICS, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| CN-112645866-A | Synthesis and application of 1-benzyl-4-methyl-5-alkoxy-1, 2,3, 6-tetrahydropyridine derivative | 浙江奥翔药业股份有限公司 | 2021-04-13 | — | — | CN | disclosed |
| US-10961247-B2 | Pyrazolopyrimidine derivatives as kinase inhibitor | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2021-03-30 | — | — | US | disclosed |
| EP-3539965-B1 | AN IMPROVED PROCESS FOR THE PREPARATION OF (3R,4R)-(1-BENZYL-4-METHYLPIPERIDIN-3-YL)-METHYLAMINE | UNICHEM LAB LTD (IN) | 2021-01-20 | — | — | EP | disclosed |
| US-10829450-B2 | Process for the preparation of (3R,4R)-(1-benzyl-4-methylpiperidin-3-yl)-methylamine | UNICHEM LABORATORIES LIMITED (IN) | 2020-11-10 | — | — | US | disclosed |
| US-10829450-B2 | Process for the preparation of (3R,4R)-(1-benzyl-4-methylpiperidin-3-yl)-methylamine | UNICHEM LABORATORIES LIMITED (IN) | 2020-11-10 | — | — | US | disclosed |
| US-10829450-B2 | Process for the preparation of (3R,4R)-(1-benzyl-4-methylpiperidin-3-yl)-methylamine | UNICHEM LABORATORIES LIMITED (IN) | 2020-11-10 | — | — | US | disclosed |
| US-10829450-B2 | Process for the preparation of (3R,4R)-(1-benzyl-4-methylpiperidin-3-yl)-methylamine | UNICHEM LABORATORIES LIMITED (IN) | 2020-11-10 | — | — | US | disclosed |
| US-20200317673-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS KINASE INHIBITOR | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2020-10-08 | — | — | US | disclosed |
| WO-2020204647-A1 | PROCESSES FOR PREPARING (3R,4R)-1-BENZYL-N,4-DIMETHYLPIPERIDIN-3-AMINE OR A SALT THEREOF AND PROCESSES FOR PREPARING TOFACITINIB USING THE SAME | YUHAN CORPORATION (KR) | 2020-10-08 | — | — | WO | disclosed |
| WO-2020204647-A1 | PROCESSES FOR PREPARING (3R,4R)-1-BENZYL-N,4-DIMETHYLPIPERIDIN-3-AMINE OR A SALT THEREOF AND PROCESSES FOR PREPARING TOFACITINIB USING THE SAME | YUHAN CORPORATION (KR) | 2020-10-08 | — | — | WO | disclosed |
| WO-2020204647-A1 | PROCESSES FOR PREPARING (3R,4R)-1-BENZYL-N,4-DIMETHYLPIPERIDIN-3-AMINE OR A SALT THEREOF AND PROCESSES FOR PREPARING TOFACITINIB USING THE SAME | YUHAN CORPORATION (KR) | 2020-10-08 | — | — | WO | disclosed |
| WO-2020183295-A1 | PROCESS FOR PREPARATION OF TOFACITINIB AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | INTAS PHARMACEUTICALS LTD. (IN) | 2020-09-17 | — | — | WO | disclosed |
| US-20200283437-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2020-09-10 | — | — | US | disclosed |
| US-10654850-B2 | Pyridazinones and methods of use thereof | GOLDFINCH BIO, INC. (US) | 2020-05-19 | — | — | US | disclosed |
| CN-105732637-B | Heteroaromatic compounds and their use in medicine | 广东东阳光药业有限公司 | 2020-04-21 | — | — | CN | disclosed |
| US-20200102301-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2020-04-02 | — | — | US | disclosed |
| EP-3539965-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF (3R,4R)-(1-BENZYL-4-METHYLPIPERIDIN-3-YL)-METHYLAMINE | UNICHEM LABORATORIES LIMITED (IN) | 2019-09-18 | — | — | EP | disclosed |
| EP-3539965-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF (3R,4R)-(1-BENZYL-4-METHYLPIPERIDIN-3-YL)-METHYLAMINE | UNICHEM LABORATORIES LIMITED (IN) | 2019-09-18 | — | — | EP | disclosed |
| US-20190135808-A1 | SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME | ACLARIS THERAPEUTICS, INC. | 2019-05-09 | — | — | US | disclosed |
| US-20190135808-A1 | SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME | ACLARIS THERAPEUTICS, INC. | 2019-05-09 | — | — | US | disclosed |
| EP-3421455-B1 | IMPROVED PROCESS FOR THE PREPARATION OF CHIRAL 3-AMINO-PIPERIDINS, USEFUL INTERMEDIATES FOR THE PREPARATION OF TOFACITINIB | FIS FABBRICA ITALIANA SINTETICI SPA (IT) | 2019-03-27 | — | — | EP | disclosed |
| EP-3421455-B1 | IMPROVED PROCESS FOR THE PREPARATION OF CHIRAL 3-AMINO-PIPERIDINS, USEFUL INTERMEDIATES FOR THE PREPARATION OF TOFACITINIB | FIS FABBRICA ITALIANA SINTETICI SPA (IT) | 2019-03-27 | — | — | EP | disclosed |
| US-20190002407-A1 | PROCESS FOR THE PREPARATION OF CHIRAL 3-AMINO-PIPERIDINS, USEFUL INTERMEDIATES FOR THE PREPARATION OF TOFACITINIB | F.I.S. - FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2019-01-03 | — | — | US | disclosed |
| US-20190002407-A1 | PROCESS FOR THE PREPARATION OF CHIRAL 3-AMINO-PIPERIDINS, USEFUL INTERMEDIATES FOR THE PREPARATION OF TOFACITINIB | F.I.S. - FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2019-01-03 | — | — | US | disclosed |
| EP-3421455-A1 | IMPROVED PROCESS FOR THE PREPARATION OF CHIRAL 3-AMINO-PIPERIDINS, USEFUL INTERMEDIATES FOR THE PREPARATION OF TOFACITINIB | F.I.S.- Fabbrica Italiana Sintetici S.p.A. (IT) | 2019-01-02 | — | — | EP | disclosed |
| EP-3421455-A1 | IMPROVED PROCESS FOR THE PREPARATION OF CHIRAL 3-AMINO-PIPERIDINS, USEFUL INTERMEDIATES FOR THE PREPARATION OF TOFACITINIB | F.I.S.- Fabbrica Italiana Sintetici S.p.A. (IT) | 2019-01-02 | — | — | EP | disclosed |
| US-20180134661-A1 | Process for the Preparation of (3R,4R)-(1-BENZYL-4-METHYLPIPERIDIN-3-YL)-METHYLAMINE | UNICHEM LAB LTD (IN) | 2018-05-17 | — | — | US | disclosed |
| US-20180134661-A1 | Process for the Preparation of (3R,4R)-(1-BENZYL-4-METHYLPIPERIDIN-3-YL)-METHYLAMINE | UNICHEM LAB LTD (IN) | 2018-05-17 | — | — | US | disclosed |
| US-20180134661-A1 | Process for the Preparation of (3R,4R)-(1-BENZYL-4-METHYLPIPERIDIN-3-YL)-METHYLAMINE | UNICHEM LAB LTD (IN) | 2018-05-17 | — | — | US | disclosed |
| US-20180134661-A1 | Process for the Preparation of (3R,4R)-(1-BENZYL-4-METHYLPIPERIDIN-3-YL)-METHYLAMINE | UNICHEM LAB LTD (IN) | 2018-05-17 | — | — | US | disclosed |
| US-9951012-B2 | Process for the preparation of (3R,4R)-(1-benzyl-4-methylpiperidin-3-yl)-methylamine | UNICHEM LABORATORIES LIMITED (IN) | 2018-04-24 | — | — | US | disclosed |
| US-9951012-B2 | Process for the preparation of (3R,4R)-(1-benzyl-4-methylpiperidin-3-yl)-methylamine | UNICHEM LABORATORIES LIMITED (IN) | 2018-04-24 | — | — | US | disclosed |
| US-9951012-B2 | Process for the preparation of (3R,4R)-(1-benzyl-4-methylpiperidin-3-yl)-methylamine | UNICHEM LABORATORIES LIMITED (IN) | 2018-04-24 | — | — | US | disclosed |
| US-9951012-B2 | Process for the preparation of (3R,4R)-(1-benzyl-4-methylpiperidin-3-yl)-methylamine | UNICHEM LABORATORIES LIMITED (IN) | 2018-04-24 | — | — | US | disclosed |
| US-9951012-B2 | Process for the preparation of (3R,4R)-(1-benzyl-4-methylpiperidin-3-yl)-methylamine | UNICHEM LABORATORIES LIMITED (IN) | 2018-04-24 | — | — | US | disclosed |
| WO-2018060512-A1 | PROCESS FOR PREPARING CHIRAL AMINES | PATHEON AUSTRIA GMBH & CO KG (AT) | 2018-04-05 | — | — | WO | disclosed |
| EP-3301087-A1 | PROCESS FOR PREPARING CHIRAL AMINES | DPx Fine Chemicals Austria GmbH & Co KG (AT) | 2018-04-04 | — | — | EP | disclosed |
| EP-2671882-B1 | pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2m3-b]pyrimidin-4-yl-amines as janus kinase inhibitors | INCYTE HOLDINGS CORP (US) | 2018-02-21 | — | — | EP | disclosed |
| US-20180037551-A1 | Process for the Preparation of (3R,4R)-(1-BENZYL-4-METHYLPIPERIDIN-3-YL)-METHYLAMINE | UNICHEM LAB LTD (IN) | 2018-02-08 | — | — | US | disclosed |
| US-20180037551-A1 | Process for the Preparation of (3R,4R)-(1-BENZYL-4-METHYLPIPERIDIN-3-YL)-METHYLAMINE | UNICHEM LAB LTD (IN) | 2018-02-08 | — | — | US | disclosed |
| US-20180037551-A1 | Process for the Preparation of (3R,4R)-(1-BENZYL-4-METHYLPIPERIDIN-3-YL)-METHYLAMINE | UNICHEM LAB LTD (IN) | 2018-02-08 | — | — | US | disclosed |
| US-20180037551-A1 | Process for the Preparation of (3R,4R)-(1-BENZYL-4-METHYLPIPERIDIN-3-YL)-METHYLAMINE | UNICHEM LAB LTD (IN) | 2018-02-08 | — | — | US | disclosed |
| US-9879010-B2 | Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b] pyrimidin-5-yl-amines as Janus kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170349579-A1 | PYRROLO[2,3-B]PYRIDIN-4-YL-AMINES AND PYRROLO[2,3-B]PYRIMIDIN-5-YL-AMINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2017-12-07 | — | — | US | disclosed |
| US-9828380-B2 | Efficient method for the preparation of tofacitinib citrate | OLON S.P.A. (IT) | 2017-11-28 | — | — | US | disclosed |
| US-9828380-B2 | Efficient method for the preparation of tofacitinib citrate | OLON S.P.A. (IT) | 2017-11-28 | — | — | US | disclosed |
| US-20170240510-A1 | PROCESS FOR THE PREPARATION OF (3R,4R)-(1-BENZYL-4-METHYLPIPERIDIN-3-YL)-METHYLAMINE | UNICHEM LAB LTD (IN) | 2017-08-24 | — | — | US | disclosed |
| US-20170240510-A1 | PROCESS FOR THE PREPARATION OF (3R,4R)-(1-BENZYL-4-METHYLPIPERIDIN-3-YL)-METHYLAMINE | UNICHEM LAB LTD (IN) | 2017-08-24 | — | — | US | disclosed |
| US-20170240510-A1 | PROCESS FOR THE PREPARATION OF (3R,4R)-(1-BENZYL-4-METHYLPIPERIDIN-3-YL)-METHYLAMINE | UNICHEM LAB LTD (IN) | 2017-08-24 | — | — | US | disclosed |
| US-20170240510-A1 | PROCESS FOR THE PREPARATION OF (3R,4R)-(1-BENZYL-4-METHYLPIPERIDIN-3-YL)-METHYLAMINE | UNICHEM LAB LTD (IN) | 2017-08-24 | — | — | US | disclosed |
| US-9580419-B2 | Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| US-20160297825-A1 | EFFICIENT METHOD FOR THE PREPARATION OF TOFACITINIB CITRATE | OLON S.P.A. (IT) | 2016-10-13 | — | — | US | disclosed |
| US-20160297825-A1 | EFFICIENT METHOD FOR THE PREPARATION OF TOFACITINIB CITRATE | OLON S.P.A. (IT) | 2016-10-13 | — | — | US | disclosed |
| EP-3078665-A1 | EFFICIENT METHOD FOR THE PREPARATION OF TOFACITINIB CITRATE | OLON S.p.A. (IT) | 2016-10-12 | — | — | EP | disclosed |
| US-20160122354-A1 | PROCESS FOR THE PREPARATION OF (3R,4R)-4-METHYL-3-(METHYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL-AMINO)-ß-OXO-1-PIPERIDINEPROPANENITRILE AND ITS SALTS | THIRUMALAI RAJAN SRINIVASAN (IN) | 2016-05-05 | — | — | US | disclosed |
| US-20160122354-A1 | PROCESS FOR THE PREPARATION OF (3R,4R)-4-METHYL-3-(METHYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL-AMINO)-ß-OXO-1-PIPERIDINEPROPANENITRILE AND ITS SALTS | THIRUMALAI RAJAN SRINIVASAN (IN) | 2016-05-05 | — | — | US | disclosed |
| US-20160122354-A1 | PROCESS FOR THE PREPARATION OF (3R,4R)-4-METHYL-3-(METHYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL-AMINO)-ß-OXO-1-PIPERIDINEPROPANENITRILE AND ITS SALTS | THIRUMALAI RAJAN SRINIVASAN (IN) | 2016-05-05 | — | — | US | disclosed |
| US-20160102057-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF (3R,4R)-(1-BENZYL-4-METHYLPIPERIDIN-3-YL)-METHYLAMINE | UNICHEM LABORATORIES LIMITED (IN) | 2016-04-14 | — | — | US | disclosed |
| US-20160102057-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF (3R,4R)-(1-BENZYL-4-METHYLPIPERIDIN-3-YL)-METHYLAMINE | UNICHEM LABORATORIES LIMITED (IN) | 2016-04-14 | — | — | US | disclosed |
| US-20160102057-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF (3R,4R)-(1-BENZYL-4-METHYLPIPERIDIN-3-YL)-METHYLAMINE | UNICHEM LABORATORIES LIMITED (IN) | 2016-04-14 | — | — | US | disclosed |
| US-20160102057-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF (3R,4R)-(1-BENZYL-4-METHYLPIPERIDIN-3-YL)-METHYLAMINE | UNICHEM LABORATORIES LIMITED (IN) | 2016-04-14 | — | — | US | disclosed |
| EP-2994454-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF (3R,4R)-(1-BENZYL-4-METHYLPIPERIDIN-3-YL)-METHYLAMINE | UNICHEM LABORATORIES LIMITED (IN) | 2016-03-16 | — | — | EP | disclosed |
| EP-2994454-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF (3R,4R)-(1-BENZYL-4-METHYLPIPERIDIN-3-YL)-METHYLAMINE | UNICHEM LABORATORIES LIMITED (IN) | 2016-03-16 | — | — | EP | disclosed |
| US-20150315185-A1 | PYRROLO[2,3-b]PYRIDIN-4-YL-AMINES AND PYRROLO[2,3-b]PYRIMIDIN-5-YL-AMINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2015-11-05 | — | — | US | disclosed |
| US-9090611-B2 | Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as janus kinase inhibitors | INCYTE CORPORATION (US) | 2015-07-28 | — | — | US | disclosed |
| WO-2015087201-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF (3R,4R)-(1-BENZYL-4-METHYLPIPERIDIN-3-YL)-METHYLAMINE | UNICHEM LABORATORIES LIMITED (IN) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015087201-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF (3R,4R)-(1-BENZYL-4-METHYLPIPERIDIN-3-YL)-METHYLAMINE | UNICHEM LABORATORIES LIMITED (IN) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015087201-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF (3R,4R)-(1-BENZYL-4-METHYLPIPERIDIN-3-YL)-METHYLAMINE | UNICHEM LABORATORIES LIMITED (IN) | 2015-06-18 | — | — | WO | disclosed |
| EP-1828181-B1 | PYRROLO[2,3-B]PYRIDIN-4-YL-AMINES AND PYRROLO[2M3-B]PYRIMIDIN-4-YL-AMINES AS JANUS KINASE INHIBITORS | INCYTE CORP (US) | 2015-02-18 | — | — | EP | disclosed |
| US-20140228346-A1 | PYRROLO[2,3-b]PYRIDIN-4-YL-AMINES AND PYRROLO[2,3-b]PYRIMIDIN-5-YL-AMINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2014-08-14 | — | — | US | disclosed |
| US-8741895-B2 | Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2014-06-03 | — | — | US | disclosed |
| EP-2671882-A1 | pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2m3-b]pyrimidin-4-yl-amines as janus kinase inhibitors | Incyte Corporation (US) | 2013-12-11 | — | — | EP | disclosed |
| US-20130296299-A1 | PYRROLO[2,3-b]PYRIDIN-4-YL-AMINES AND PYRROLO[2,3-b]PYRIMIDIN-5-YL-AMINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2013-11-07 | — | — | US | disclosed |
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-08-22 | — | — | US | disclosed |
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-08-22 | — | — | US | disclosed |
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-08-22 | — | — | US | disclosed |
| US-8445488-B2 | Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2013-05-21 | — | — | US | disclosed |
| US-8309716-B2 | Pyrrolo[2,3-d]pyrimidine derivatives: their intermediates and synthesis | PFIZER INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20120259115-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES: THEIR INTERMEDIATES AND SYNTHESIS | PFIZER INC. (US) | 2012-10-11 | — | — | US | disclosed |
| US-8232394-B2 | Pyrrolo[2,3-d]pyrimidine derivatives; their intermediates and synthesis | PFIZER INC. (US) | 2012-07-31 | — | — | US | disclosed |
| EP-2470537-A2 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-07-04 | — | — | EP | disclosed |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149691-A1 | Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149691-A1 | Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-8163767-B2 | Heterocyclic Janus Kinase 3 inhibitors | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20120014989-A1 | PYRROLO[2,3-b]PYRIDIN-4-YL-AMINES AND PYRROLO[2,3-b]PYRIMIDIN-5-YL-AMINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION, A DELAWARE CORPORATION | 2012-01-19 | — | — | US | disclosed |
| US-20110288297-A1 | Pyrrolo[2,3-d]Pyrimidine Derivatives; Their Intermediates and Synthesis | PFIZER, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| US-8053433-B2 | Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as janus kinase inhibitors | Ineyte Corporation (US) | 2011-11-08 | — | — | US | disclosed |
| US-20110165183-A1 | PIPERIDINE DERIVATIVES AS JAK3 INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110165183-A1 | PIPERIDINE DERIVATIVES AS JAK3 INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| WO-2011076419-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2011-06-30 | — | — | WO | disclosed |
| EP-2338888-A1 | Imidazopyridine derivatives as JAK inhibitors | Almirall, S.A. (ES) | 2011-06-29 | — | — | EP | disclosed |
| EP-2338888-A1 | Imidazopyridine derivatives as JAK inhibitors | Almirall, S.A. (ES) | 2011-06-29 | — | — | EP | disclosed |
| US-20110086835-A1 | Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as janus kinase inhibitors | INCYTE CORPORATION, A DELAWARE CORPORATION | 2011-04-14 | — | — | US | disclosed |
| WO-2011031554-A2 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
| WO-2011014817-A1 | PYRROLO [1, 2-B] PYRIDAZINE DERIVATIVES AS JANUS KINASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-02-03 | — | — | WO | disclosed |
| EP-2251341-A1 | Heterocyclic Janus kinase 3 inhibitors | Astellas Pharma Inc. (JP) | 2010-11-17 | — | — | EP | disclosed |
| WO-2010014930-A2 | THERAPEUTIC AGENTS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2010-02-04 | — | — | WO | disclosed |
| US-20090264399-A1 | HETEROCYCLIC JANUS KINASE 3 INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2009-10-22 | — | — | US | disclosed |
| US-7432370-B2 | Mixing a racemic mixture of enantiomers of pyrrolo[2,3-d]pyrimidine compounds in a solvent, with a resolving compound having a defined stereospecificity, to form a solution and with resolving agent being capable of binding with enantiomers to form a precipitate collecting precipitate and purifying | PFIZER INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432370-B2 | Mixing a racemic mixture of enantiomers of pyrrolo[2,3-d]pyrimidine compounds in a solvent, with a resolving compound having a defined stereospecificity, to form a solution and with resolving agent being capable of binding with enantiomers to form a precipitate collecting precipitate and purifying | PFIZER INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-7335667-B2 | Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-4-yl-amines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2008-02-26 | — | — | US | disclosed |
| US-7301023-B2 | Chiral salt resolution | PFIZER INC. (US) | 2007-11-27 | — | — | US | disclosed |
| US-7301023-B2 | Chiral salt resolution | PFIZER INC. (US) | 2007-11-27 | — | — | US | disclosed |
| EP-1828181-A2 | PYRROLO[2,3-B]PYRIDIN-4-YL-AMINES AND PYRROLO[2M3-B]PYRIMIDIN-4-YL-AMINES AS JANUS KINASE INHIBITORS | Incyte Corporation (US) | 2007-09-05 | — | — | EP | disclosed |
| US-20060183906-A1 | Use as anticancer agents, immunosuppressants for transplants or autoimmune diseases, or against immune reactions (e.g. contact dermatitis or diarrhea) caused by other drugs; e.g. 3-(3-[methyl(1H-pyrrolo[2,3-b]pyridin-4-yl)amino]piperidin-1-yl)-3-oxopropanenitrile | INCYTE CORPORATION | 2006-08-17 | — | — | US | disclosed |
| WO-2006069080-A2 | PYRROLO[2,3-B]PYRIDIN-4-YL-AMINES AND PYRROLO[2M3-B]PYRIMIDIN-4-YL-AMINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2006-06-29 | — | — | WO | disclosed |
| WO-2006069080-A2 | PYRROLO[2,3-B]PYRIDIN-4-YL-AMINES AND PYRROLO[2M3-B]PYRIMIDIN-4-YL-AMINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (43 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110165183-A1 | PIPERIDINE DERIVATIVES AS JAK3 INHIBITORS | JAK3, JAK2, JAK1 | ACHE 4871/4885BCHE 4767/4885BACE1 4680/4885 |
| US-20120149691-A1 | Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors | JAK1, JAK2, JAK3 | ACHE 4861/4885BCHE 4820/4885BACE1 4767/4885 |
| US-20220144774-A1 | PROCESSES FOR PREPARING (3R,4R)-1-BENZYL-N,4-DIMETHYLPIPERIDIN-3-AMINE OR A SALT THEREOF AND PROCESSES FOR PREPARING TOFACITINIB USING THE SAME | JAK3, JAK1, JAK2 | ACHE 4595/4885BCHE 4216/4885BACE1 4591/4885 |
| US-20240279179-A1 | SYNTHESIS AND USE OF 1-BENZYL-4-METHYL-5-ALKOXY-1,2,3,6-TETRAHYDROPYRIDINE DERIVATIVE | JAK1, JAK2, JAK3 | ACHE 4715/4885BCHE 3947/4885BACE1 4072/4885 |
| US-20180037551-A1 | Process for the Preparation of (3R,4R)-(1-BENZYL-4-METHYLPIPERIDIN-3-YL)-METHYLAMINE | KDM4D, KDM4A, KDM4C | ACHE 687/4885BCHE 972/4885BACE1 3498/4885 |
| US-20200317673-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS KINASE INHIBITOR | MAP3K5, MAP3K2, MAPKAPK5 | ACHE 3999/4885BCHE 3524/4885BACE1 3804/4885 |
| US-20220024917-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | ATP6V1B1, GLS, REN | ACHE 358/4885BCHE 1497/4885BACE1 3153/4885 |
| US-20120259115-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES: THEIR INTERMEDIATES AND SYNTHESIS | DPYD, CPS1, TYMS | ACHE 4467/4885BCHE 4683/4885BACE1 4322/4885 |
| US-20180134661-A1 | Process for the Preparation of (3R,4R)-(1-BENZYL-4-METHYLPIPERIDIN-3-YL)-METHYLAMINE | KDM4D, KDM4A, KDM4C | ACHE 687/4885BCHE 972/4885BACE1 3498/4885 |
| US-10981906-B2 | Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same | JAK3, JAK1, JAK2 | ACHE 4642/4885BCHE 4606/4885BACE1 3926/4885 |
| US-10829450-B2 | Process for the preparation of (3R,4R)-(1-benzyl-4-methylpiperidin-3-yl)-methylamine | KDM4D, KDM4A, KDM4C | ACHE 687/4885BCHE 972/4885BACE1 3498/4885 |
| US-20110086835-A1 | Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as janus kinase inhibitors | JAK3, JAK1, JAK2 | ACHE 4478/4885BCHE 4111/4885BACE1 4301/4885 |
| US-20170349579-A1 | PYRROLO[2,3-B]PYRIDIN-4-YL-AMINES AND PYRROLO[2,3-B]PYRIMIDIN-5-YL-AMINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | ACHE 4478/4885BCHE 4111/4885BACE1 4301/4885 |
| US-12281111-B2 | Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same | JAK3, JAK1, JAK2 | ACHE 4642/4885BCHE 4606/4885BACE1 3926/4885 |
| US-20060183906-A1 | Use as anticancer agents, immunosuppressants for transplants or autoimmune diseases, or against immune reactions (e.g. contact dermatitis or diarrhea) caused by other drugs; e.g. 3-(3-[methyl(1H-pyrrolo[2,3-b]pyridin-4-yl)amino]piperidin-1-yl)-3-oxopropanenitrile | JAK1, ZAP70, LCK | ACHE 2984/4885BCHE 2540/4885BACE1 4673/4885 |
| US-12227478-B2 | Processes for preparing (3R,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine or a salt thereof and processes for preparing tofacitinib using the same | JAK3, JAK1, JAK2 | ACHE 4623/4885BCHE 4223/4885BACE1 4459/4885 |
| US-20160102057-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF (3R,4R)-(1-BENZYL-4-METHYLPIPERIDIN-3-YL)-METHYLAMINE | KDM4D, KDM4A, KDM4C | ACHE 725/4885BCHE 869/4885BACE1 3256/4885 |
| US-20220153743-A1 | PROCESS FOR PREPARATION OF TOFACITINIB AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | JAK3, JAK1, JAK2 | ACHE 4871/4885BCHE 4829/4885BACE1 4773/4885 |
| US-20220152031-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GLS, ATP6V1B1, PDXK | ACHE 1795/4885BCHE 2163/4885BACE1 4175/4885 |
| US-20130296299-A1 | PYRROLO[2,3-b]PYRIDIN-4-YL-AMINES AND PYRROLO[2,3-b]PYRIMIDIN-5-YL-AMINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | ACHE 4478/4885BCHE 4111/4885BACE1 4301/4885 |
| US-20160297825-A1 | EFFICIENT METHOD FOR THE PREPARATION OF TOFACITINIB CITRATE | IDH1, AURKC, COASY | ACHE 4302/4885BCHE 3265/4885BACE1 4723/4885 |
| US-20260062410-A1 | SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME | JAK3, JAK1, JAK2 | ACHE 4527/4885BCHE 4732/4885BACE1 3033/4885 |
| US-20200102301-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | ATP6V1B1, GLS, REN | ACHE 358/4885BCHE 1497/4885BACE1 3153/4885 |
| US-20240067643-A1 | SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME | JAK3, JAK1, JAK2 | ACHE 4642/4885BCHE 4606/4885BACE1 3926/4885 |
| US-20210284637-A1 | SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME | JAK3, JAK1, JAK2 | ACHE 4642/4885BCHE 4606/4885BACE1 3926/4885 |
| US-20150315185-A1 | PYRROLO[2,3-b]PYRIDIN-4-YL-AMINES AND PYRROLO[2,3-b]PYRIMIDIN-5-YL-AMINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | ACHE 4478/4885BCHE 4111/4885BACE1 4301/4885 |
| US-20090264399-A1 | HETEROCYCLIC JANUS KINASE 3 INHIBITORS | JAK3, JAK2, JAK1 | ACHE 4829/4885BCHE 4535/4885BACE1 4363/4885 |
| US-20160122354-A1 | PROCESS FOR THE PREPARATION OF (3R,4R)-4-METHYL-3-(METHYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL-AMINO)-ß-OXO-1-PIPERIDINEPROPANENITRILE AND ITS SALTS | CYP4B1, CYP3A4, CYP1B1 | ACHE 2330/4885BCHE 3516/4885BACE1 443/4885 |
| US-11046690-B2 | Pyridazinones and methods of use thereof | ATP6V1B1, GLS, REN | ACHE 358/4885BCHE 1497/4885BACE1 3153/4885 |
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | ACHE 4679/4885BCHE 4783/4885BACE1 4859/4885 |
| US-20190002407-A1 | PROCESS FOR THE PREPARATION OF CHIRAL 3-AMINO-PIPERIDINS, USEFUL INTERMEDIATES FOR THE PREPARATION OF TOFACITINIB | JAK3, JAK2, JAK1 | ACHE 4734/4885BCHE 4586/4885BACE1 4365/4885 |
| US-20140228346-A1 | PYRROLO[2,3-b]PYRIDIN-4-YL-AMINES AND PYRROLO[2,3-b]PYRIMIDIN-5-YL-AMINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | ACHE 4478/4885BCHE 4111/4885BACE1 4301/4885 |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | ACHE 4814/4885BCHE 4643/4885BACE1 4731/4885 |
| US-20200283437-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | ATP6V1B1, GLS, REN | ACHE 358/4885BCHE 1497/4885BACE1 3153/4885 |
| US-20110288297-A1 | Pyrrolo[2,3-d]Pyrimidine Derivatives; Their Intermediates and Synthesis | DPYD, CPS1, TYMS | ACHE 4478/4885BCHE 4680/4885BACE1 4391/4885 |
| US-11827598-B1 | Preparation method of tofacitinib citrate | JAK3, JAK2, JAK1 | ACHE 4561/4885BCHE 4255/4885BACE1 4820/4885 |
| US-10654850-B2 | Pyridazinones and methods of use thereof | ATP6V1B1, GLS, REN | ACHE 358/4885BCHE 1497/4885BACE1 3153/4885 |
| US-11739086-B2 | Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same | JAK3, JAK1, JAK2 | ACHE 4642/4885BCHE 4606/4885BACE1 3926/4885 |
| US-20170240510-A1 | PROCESS FOR THE PREPARATION OF (3R,4R)-(1-BENZYL-4-METHYLPIPERIDIN-3-YL)-METHYLAMINE | KDM4D, KDM4A, KDM4C | ACHE 687/4885BCHE 972/4885BACE1 3498/4885 |
| US-10961247-B2 | Pyrazolopyrimidine derivatives as kinase inhibitor | MAP3K5, MAP3K2, MAPKAPK5 | ACHE 3999/4885BCHE 3524/4885BACE1 3804/4885 |
| US-20220402924-A1 | PROCESS FOR THE PREPARATION OF TOFACITINIB AND INTERMEDIATES THEREOF | MCCC2, JAK1, JAK3 | ACHE 4509/4885BCHE 3823/4885BACE1 4731/4885 |
| US-20190135808-A1 | SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME | JAK3, JAK1, JAK2 | ACHE 4642/4885BCHE 4606/4885BACE1 3926/4885 |
| US-20120014989-A1 | PYRROLO[2,3-b]PYRIDIN-4-YL-AMINES AND PYRROLO[2,3-b]PYRIMIDIN-5-YL-AMINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | ACHE 4478/4885BCHE 4111/4885BACE1 4301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.